Allergan’s Phase III Botox trial for depression pushed to H2 2019
Allergan’s Botox (onabotulinumtoxin A) Phase III trial in major depressive disorder (MDD) is slated...
Trending:
-
![FMX103 sunburn impact]()
Foamix’s rosacea drug FMX103 splits views on sunburn risk
-
![]()
Pat-INFORMED: the solution to drug patent procurement issues?
-
![Mylan valsartan-containing drugs recall]()
Mylan recalls all lots of blood pressure drugs containing valsartan
-
![Haemophilia A treatment options]()
Can Bayer’s Jivi match up to the competition in haemophilia A market?
-
![UCB]()
UCB to invest £1bn in the UK Life Sciences Sector Deal
-
![Non-Hodgkin’s Lymphoma]()
Label expansion is a common strategy in Non-Hodgkin’s Lymphoma
Most Read
- Pat-INFORMED: the solution to drug patent procurement issues?
- Mylan recalls all lots of blood pressure drugs containing valsartan
- UCB to invest £1bn in the UK Life Sciences Sector Deal
- Gut health: are probiotics as effective as consumers believe?
- Four new Pfizer brands will help make up for looming Lyrica patent expiry
Company A-Z
Latest Content
Allergan’s Phase III Botox trial for depression pushed to H2 2019
Allergan’s Botox (onabotulinumtoxin A) Phase III trial in major depressive disorder (MDD) is slated to initiate in the second half of 2019 (2H19), said a company spokesperson.
Foamix’s rosacea drug FMX103 splits views on sunburn risk
Foamix Pharmaceuticals’ FMX103 (1.5% topical minocycline foam) has experts split over the drug’s real-world ability to protect against sunburn, despite expected FDA approval for moderate-to-severe facial papulopustular rosacea.
M&As this week: GlaxoSmithKline, Takeda, Procter & Gamble
GlaxoSmithKline (GSK) has agreed to acquire US-based cancer treatment developer Tesaro for $5.1bn.
November’s top stories
Sobi has signed agreements to acquire the rights to AstraZeneca’s Synagis medicine in the US for an upfront payment of $1.5bn, and Takeda Pharmaceutical has received a conditional approval from the EC for the $62bn proposed acquisition of Irish biopharmaceutical company Shire. Pharmaceutical-technology.com wraps up key headlines from November 2018.
Deals this week: Boehringer Ingelheim, UCB, Janssen Pharmaceutical
Boehringer Ingelheim and Domain Therapeutics have entered a deal to collaborate on a drug discovery project.
Pat-INFORMED: the solution to drug patent procurement issues?
Many countries do not have the equivalent to the US’s Orange book, meaning that health officials are wasting time establishing whether patents have been taken out on medicines. Leading biopharmaceutical companies have worked together to develop Pat-INFORMED, a new global platform that could allow government procurement agencies to access information on thousands of individual patents anywhere in the world.
Mylan recalls all lots of blood pressure drugs containing valsartan
Mylan has expanded the consumer-level voluntary recall of all lots of valsartan-containing drugs within expiry in the US after finding trace amounts of an impurity called N-nitrosodiethylamine (NDEA).
Can Bayer’s Jivi match up to the competition in haemophilia A market?
Jivi received EU approval based on results of the Phase II/III PROTECT VIII trial, in which prophylactic dosing, on-demand treatment, and perioperative management were assessed in patients.
Takeda receives shareholders’ approval to acquire Shire
Takeda Pharmaceutical has secured shareholder approval for the issuance of its shares necessary to implement the proposed $62bn acquisition of Shire.
UCB to invest £1bn in the UK Life Sciences Sector Deal
Belgian biopharmaceutical company UCB has agreed to invest approximately £1bn ($1.27bn) as part of a collaboration between the UK government and life sciences industry intended to support healthcare innovation in the country.
Latest News
Read our magazine
Pharma Technology Focus is the essential reading material for decision-makers in the pharmaceutical industry, bringing you the latest news and analysis in an exciting, interactive format.
